which takes only SNPs as basic units of association analysis has a few serious limitations. First, the single SNP showing significant association with complex diseases typically has only mild effects 13 . The common disease often arises from joint action of multiple loci within a gene or joint action of multiple genes within a pathway. Although each single SNP may confer small disease risk, their joint actions will play a significant role in the development of disease. If we only consider the most significant SNPs, the genetic variants that jointly have significant risk effects, but individually make only a small contribution, will be missed. Second, locus heterogeneity, in which alleles at different loci cause disease in different populations, will increase difficulty in replication of association of single marker 14 . The list of significant SNPs from several studies may rarely overlap. A gene, particularly, a pathway, consists of a group of interacting components acting in concert to perform specific biological tasks. Replication of association finding at the gene level or pathway level is much easier than replication at the SNP level. Third, attempting to understand and interpret a number of significant SNPs without any unifying biological theme can be challenging and demanding. SNPs and genes carry out their functions through intricate pathways of reactions and interaction. The function of many SNPs may not be well characterized, but function of genes and particularly pathways, on the contrary, are much better investigated. Therefore, the gene and pathway-based association analysis should allow to gain insight into the functional basis of the association and facilitate to unravel the mechanism of complex diseases.
To meet conceptual and technical challenge raised by GWAS and take full advantage of the huge opportunities provided by GWAS, a complementary approach to genome-wide search association of single SNP with the disease is gene and pathway association analysis. The gene and pathway-based association analysis is to take a gene or pathway as a basic unit of analysis.
The gene and pathway-based GWAS aim to simultaneously study association of a group of genetic variants in the same biological pathway [14] [15] [16] , which help us to holistically unravel complex genetic structure of common disease to gain insight into the biological processes and disease mechanism 17 .
The gene and pathway-based GWAS can be performed by extension of gene set enrichment analysis for gene expression data, which intend to identify subtle, but coordinated expression variations of gene groups 18 , to genome-wide association studies. This will open a new avenue for association analysis. However, simple application of gene set analysis methods for gene expression data to GWAS may not work very well. The key difference between the gene expression data and SNP data is that in expression data each gene is represented by one value of expression level of the gene, but in GWAS each gene is represented by a variable number of SNPs. The challenge facing us is how to represent a gene. Wang et al. 19 proposed to choose the most significant SNP from each gene as a representative. As Casci 20 pointed out "Given that each gene is associated with more than one SNP, how do you choose the most representative one?
And how do you correct for the fact that longer genes have more SNPs than shorter ones?". In other words, applying gene set enrichment analysis methods to GWAS requires developing genebased association analysis that takes gene as a basic unit of association analysis. One promising approach is to combine P-values for correlated SNPs into an overall significance level to represent a gene and to combine P-values for the genes into an overall significance level to investigate association of a pathway with the disease 21 .
RESULTS
To investigate what should be the basic units for genome-wide association studies and to illustrate how to perform the gene and pathway-based genome-wide association analysis, we examine the thirteen published GWAS (Supplementary Table 1 In principle, there are three basic units for genome-wide association studies: SNP, gene and pathway. The current GWAS are limited to taking a SNP as the basic unit for association testing.
Now we present the results where the basic unit of association tests is a gene or a pathway. The procedure for gene and pathway-based GWAS consist of two steps. The first step is to combine a set of P-values for SNPs in a gene, which is obtained from GWAS of single SNP, into an overall significance level of the gene. The second step is to combine a set of P-values for genes in a pathway into an overall P-value for the pathway. To combine P-values, one typically assumes that the P-values are independent and uniformly distributed under their null hypothesis. Although initial single SNP analysis did not find any significant SNPs in these genes, the recent meta-analysis 24 showed that the P-values of the best SNPs in these genes were 2.00 conduct the single SNP association analysis, these significant genes might be missed due to low power of small sample sizes in the initial GWAS. Second, replication of association finding that results from gene-based approach in additional independent samples were much easier than that from single SNP association analysis. We examined association studies of three diseases: T2D, PA and RA, each with two independent studies. For T2D, no SNPs were replicated in two independent studies (WTCCC and DGI) after correction for multiple test by Bonferroni method.
However, seven genes including genes TCF7L2 (transcription factor 7-like 2) and CDKAL1
(CDK5 regulatory subunit associated protein 1-like 1) were replicated (Supplementary Table   S17 ). The gene TCF7L2 which has a marked effect on type 2 diabetes was widely replicated association in several studies 2, 23 . In single SNP association analysis, although strong association of CDKAL1 was reported from WTCCC (P=1.02 Table S17 ). Although the function of CDKAL1 is unknown, nominal association of the risk allele with reduced insulin secretion in controls was reported in DGI study (P=0.01) 23 . To explain why replication of the significant gene in independent samples is much easier than replication of the significant SNP we presented Table 2 in which all SNPs with P-values < 0.05 in the genes were listed. Table 2 demonstrated that although few single SNP in the genes CDKAL1, TTLL5 and BTBD16 showed significant association in WTCCC study or DGI study, the joint effects of multiple SNPs with very mild effects made three genes to be strongly associated with the diseases in both studies. Third, the gene-based association analysis will more effectively identify the common genes that are shared within a disease group than the single SNP association analysis. Although there is considerable heterogeneity among complex diseases, many diseases share common phenotypes, forming a group of diseases. In the studies which we examined here, CD+RA+T1D are autoimmune diseases, and CAD+HT+T2D have metabolic and cardiovascular phenotypes in common. GWAS offer us opportunity to reveal the genetic variants that confer risk to more than one disease. were used to test significant association of pathway with the disease (See methods). We assembled 465 pathways from KEGG 25 and Biocarta (http://www.biocarta.com). Table 3 summarized the number of significant pathways and Table 4 summarized the number of replicated pathways associate with the diseases RA, T2D and PA in two independent studies or the number of pathways shared within the diseases CAD+HT+T2D, RA+T1D, and CD+RA+T1D in the WTCCC studies. These significant pathways were identified by overrepresentation test and analysis is a key to unraveling mechanism of complex diseases and opens a way toward a pathway definition of complex diseases. Biological pathways are sets of genes that work in concert to perform particular cellular functions or biological processes. As Table 3 shown, much larger proportion of pathways was significantly associated with the disease than that of genes, let alone
Supplementary
SNPs. This implied that pathways play essential roles in causing disease. We note that many Replications can be performed at the level of the SNP, the gene and pathway. As Table 1 shown, no significant SNPs (using Bonferroni method for correction of multiple tests) in T2D GWAS can be replicated and only seven significant genes can be replicated in the WTCCC and DGI studies.
However, 10 (Simes/FDR) or 5 (Fisher exact test) pathways can be replicated ( Clinical onset of RA also shows hormone-related pattern 30 . Typically, the peak incidence of RA in women is during menopause, while the disease in men occurs after age 45. These observations are consistent with gonadotropins associated disease mechanisms. It is interesting to note that the P-values of the best SNP in gene PRKACB, GRB2 and KRAS were 0.013, 0.006 and 0.0012, respectively. This example showed that each SNP may confer small contribution, but their joint actions may affect function of the pathway which in turn will cause disease. These results strongly challenge the current strategy for genome-wide association studies which was limited to taking only single SNP as basic unit for association testing.
DISCUSSION
In the past two years we have witnessed the success of the first wave of large-scale GWAS.
Despite rapid progress in GWAS, the most widely used approach to GWAS is individual SNP association analysis. In other words, it evaluates the significance of individual SNPs. However, this issue, we proposed to take a system biology approach, which considers not only SNP, but also gene and pathway as a basic unit of GWAS, to deciphering complex path from genotype to phenotype.
The proposed paradigm for GWAS consists of three components: SNP-based, gene-based and pathway-based association analyses. Gene and pathway-based association analysis assesses the significance of the genes and the predefined pathways, and intends to identify biological pathways with subtle but coordinated genetic variants that confer risk contributions. We performed a comprehensive gene and pathway-based GWAS for eleven diseases, assuming that the results of single SNP association analysis are available. Our results showed that the proposed new paradigm for GWAS not only identified the genes that include significant SNPs found by single SNP analysis, but also detected new genes in which each single SNP conferred small disease risk, but their joint actions were implicated in the development of diseases. We verified the new genes that were identified by the new paradigm for GWAS from two aspects. First, these new findings were replicated in two independent samples. Second, the SNPs that are located in the new identified genes were not significant in any of their original studies, but showed strong association in the recently published meta analysis of genome-wide association data and largescale replication. Our results also strongly demonstrated that replication of association finding at the gene or pathway level is much easier than replication at the individual SNP level. One of the major advantages offered by the new paradigm for GWAS is that pathway-based analysis can add structure to genomic data and allows us to gain insight into the deep understanding of cellular processes as intricate networks of functionally related genes. We further demonstrated that the new paradigm can also offer the opportunities for finding the pathways that are common within disease groups. We used RA as an example to show that the identified pathways by the new paradigm for GWAS can be confirmed by gene-set rich analysis using gene expression data.
This implies that the new paradigm for GWAS will open a novel avenue to integrate GWAS with
other functional analyses and hence will facilitate to uncover the mechanism of complex diseases.
Since the current GWAS only report the P-value for single SNP, and the individual genotype data is not publically available, our methods for gene and pathway-based GWAS are designed for the P-value data. The major tool for gene and pathway-based analyses is to combine independent P-values of single SNP in the gene into an overall P-value for the gene and independent P-values of single gene in the pathway into an overall P-value for the pathway.
Since the SNPs in a gene are often dependent, we need methods for combining dependent Pvalues, which in turn require individual genotype information. The limitation of the proposed gene and pathway-based association analysis which is based on combining independent P-values is applied to dependent data. The gene and pathway-based analysis that uses the methods to combine dependent P-values will be needed. The results of the gene and pathway-based GWAS that take correlations among the SNP and genes into account will be performed in the near future.
In the coming years we will see the rapid progress in GWAS. Many challenging tasks for GWAS are that we not only need to develop powerful statistical methods for detection of as many association of genetic variants as possible, but also need to study functional basis of association and to gain insight into deeper and deeper understanding of mechanism of complex diseases. To unravel the true nature of complex diseases can only be gained by integration of multiple approaches and multiple types of data. As a proof of concept, we showed that the gene and pathway-based GWAS can provide a general framework for combining genetic studies with other functional analyses. We expect that gene and pathway-based analysis will become second wave of large-scale GWAS.
METHODS

Gene-based association analysis.
A gene consists of a number of SNPs. Typical results for association studies are the P-values for testing association of the single SNP with the disease.
Statistics for testing association of a gene with the disease were conducted on the basis of the combination of P values of the SNPs in the gene 14 . We assume that the P-values i P are independent and uniformly distributed under their null hypotheses although independent assumption may be violated due to linkage disequilibrium (LD) among SNPs in the gene.
Several methods were used to combine independent P values. A general framework for combining independent P-values is as follows. Let i P be the p-value for corresponding statistic 21 .
Sidak Combination Test (The Best SNP)
If we consider only the best SNP in the gene, then the statistic is defined as
The distribution of B Z is given by
which is also referred to as Sidak's correction.
Simes' Combination Test
Let P-values be ordered as
. The P-value is calculated as
The FDR methods
Let π be the proportion of tests with a true null hypothesis and ) (α F be the expected proportion of tests yielding a P-value less than or equal to α , ) (α V be the expected proportion of tests resulting in a false positive with significant levelα .
Suppose that there are
Let j m be the number of P-values among p that are equal to j p .
Then,
where I is an indicator function: 
is the ordered false discovery rates.
We also take
as the false discovery rate for the gene or pathway 19 .
Pathway-based association analysis.
Consider m genes in a pathway. Assume that P-value for each gene is calculated by one of the methods to combine independent P-values in the previous section. The methods for testing association of pathway with the disease are given below.
Hypergeometric Test (Fisher Exact Test).
Fisher exact test is to search for an overrepresentation of significantly associated genes among the genes in the pathway. We assume that the total number of genes that are of interests is N. Let S be the number of genes that are significantly associated with the disease (P-value 05 . 0 ≤ and is calculated by Fisher combination test) and m be the number of genes in the pathway. Also let k be the number of genes significantly associated genes in the pathway. The P-value of observing k significant genes in the pathway is calculated by 
